Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease

Streptococcus Agalactiae Infection Clinical Trial

— iGBS3  

Official title:

Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04735419
• Other study ID #: 2020.0176
• Status: Recruiting
• Start date: December 1, 2021
• Est. completion date: March 30, 2024

Study information

• Verified date: November 2023
• Source: St George's, University of London
• Contact: Nadia Azzouzi
• Phone: 02082666488
• Email: nazzouzi[@]sgul.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A multicentre study to provide evidence that the relationship between an immune marker value (anti-GBS IgG concentration) and the probability of invasive GBS (iGBS) disease in infants less than 90 days of age is sufficiently strong that a vaccine able to induce an immune response will lead to a meaningful decrease in the probability of iGBS disease.

Description:

Group B Streptococcus (GBS) is a bacterium (a bug) that causes serious infections in young infants across the world. In 2015 it was estimated that there were at least 319,000 infants under 3 months of age with GBS disease worldwide, resulting in 90,000 deaths and at least 10,000 children with long term disabilities. Around 20% of all pregnant women carry GBS in their vagina and bowel and babies are exposed to GBS bacteria around the time of birth. The options for prevention are currently limited to offering antibiotics during labour.

A vaccine that could be given to pregnant women has the greatest potential to benefit mothers and babies worldwide. There are vaccines currently being tested in clinical trials, including in pregnant women. The iGBS3 study aims to find out what levels of immunity (usually measured as antibody) a woman needs to pass to her baby to protect the baby from getting GBS disease. This will allow us to predict what antibody level a vaccine has to achieve to be effective and then to get those vaccines licensed and implemented as quickly as possible.

To do this, the study need to take a small sample of cord blood from a very large number of women just after delivering their baby. The study will need to follow around 180 000 babies in order to find at least 170 babies with GBS disease (of which 100 will have disease with the most common type) and compare their levels of antibody in cord blood with 300 healthy babies exposed to the same GBS type. To achieve this, SGUL will work with the Nottingham Clinical Trials Unit to embed this study in their existing GBS3 Trial, in which 80 hospitals across England, Scotland and Wales will be involved for 2 years.

Study Design iGBS3 is a large, multicentre, prospective, unmatched case control study in the UK designed to compare levels of antibody in cord blood in mothers whose infants develop GBS disease (iGBS) and colonised mothers whose infants do not develop GBS disease. To achieve this, the project aim to recruit at least 170 babies with GBS disease (of which 100 will have disease with the most common type) and 300 healthy babies exposed to the same GBS type. An exploratory substudy will look into levels of antibody in cord blood in mothers whose infants develop severe bacterial or viral infections caused by pathogens other than GBS.

Duration The overall duration of the project is planned for 36 months. This includes 2 months set-up, 12 months recruitment for Phase 1, 4 months for interval analysis, 12 months recruitment for Phase 2, 6 months for final retrieval of data, analysis and write-up.

Two phases

1. Phase 1 - cord blood collection and blood from an infant at time of GBS disease to establish the correlation between antibody at time of disease and cord blood

2. Phase 2 - if Phase 1 demonstrates that the correlation is strong, then in Phase 2 collection of blood from disease cases is required only; if Phase 2 shows a weak correlation, then in Phase 2 prospective collection of cord blood will continue.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: March 30, 2024
• Est. primary completion date: March 30, 2024
• Gender: All
• Age group: 0 Days and older

Eligibility

Inclusion Criteria:

-

Exclusion Criteria:

For iGBS disease case recruitment, an infant is not eligible unless a parent/person with parental responsibility gives informed consent For iGBS disease control recruitment, a mother is not eligible unless she gives informed consent.

Related Conditions & MeSH terms

• Streptococcal Infections
• Streptococcus Agalactiae Infection

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
United Kingdom	St George's University of London	London

Sponsors (4)

Lead Sponsor	Collaborator
St George's, University of London	Medical Research Council, Public Health England, University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Risk reduction objective	• To combine case-control study results (odds ratios and antibody RCD curves at different cut-offs) with other data on antibody distribution in the population and iGBS disease risk to determine absolute risk reduction. This could then be combined with vaccine immunologic trial data when available to allow prediction of vaccine efficacy (the decrease in probability of iGBS disease in infants of vaccinated compared to unvaccinated mothers).	36 months
Other	Other pathogens sub-study	• To provide data on the relationship between antibody and infant infections caused by pathogens other than GBS	36 months
Primary	Correlates objective	• To provide initial data on the relationship between antibody and iGBS disease risk by estimating the odds ratio of iGBS disease for antibody concentrations above various thresholds for STIII	36 months
Primary	Kinetics objective	• To determine whether antibody concentrations obtained at the time of disease (acute disease sample) can be used to predict cord antibody concentrations at birth in cases of iGBS STIII disease	12 months
Secondary	Correlates other than STIII	• To provide data on the relationship between antibody and iGBS disease risk by estimating the odds ratio of iGBS disease for antibody concentrations above various thresholds for serotypes other than STIII as well as all serotypes combined	36 months
Secondary	Kinetics other than STIII	• To determine whether antibody concentrations obtained at the time of disease (acute disease sample) can be used to predict cord antibody concentrations in cases for serotypes others than STIII and to see if any declines differ by serotype	12 months
Secondary	Controls objective	• To generate sufficient controls of women colonised with STIII and other serotypes	36 months